Interferon Gamma - Specimen : 243-1

389 / 448 (87%) laboratories returned results for this distribution.
Sample 243-1 was from a 16 year old male with a persistent cough whose friend has recently been diagnosed with MTB. This sample was linked to iEQA case 286. Participants must register for the iEQA scheme to gain access to further clinical details. Please contact us if you require further information about iEQA registration.

The statistics for the VIDAS TB (EIA) method group are calculated against MLTM. However, as the minimum number of returned results required to make scoring statistically meaningful was not met for this method group, it will not be subject to variance index scoring.

Your MRVIS is	101
Your MRBIS is	-48
Your SDBIS is	110

Nil (IU/mL)

	n	Mean	SD	CV(%)
All methods [ALTM]	337	0.17	0.03	18.7
LIAISON QFTB (CLIA)	194	0.17	0.03	14.6
OTHER (Automated)	4	0.14	0.06	43.8
OTHER (Manual)	3	0.11	0.05	44.4
QuantiFERON TB (Auto ELISA)	82	0.17	0.04	24.1
QuantiFERON TB (Man ELISA)	49	0.17	0.05	31.2
SD Biosensor TB (Auto FIA)	2	0.24	0.13	54.8
VIDAS TB (EIA)	3	0.38	0.02	5.4



Your result	0.09
Target value (ALTM)	0.17
Your BIS	
Standard Uncertainty	0.00
CCV	20

TB 1 Antigen (IU/mL)

	n	Mean	SD	CV(%)
All methods [ALTM]	327	0.17	0.04	21.1
LIAISON QFTB (CLIA)	193	0.17	0.03	15.5
OTHER (Automated)	2	0.15	0.04	28.3
OTHER (Manual)	3	0.08	0.09	112.5
QuantiFERON TB (Auto ELISA)	78	0.16	0.04	24.4
QuantiFERON TB (Man ELISA)	48	0.17	0.05	31.1
VIDAS TB (EIA)	3	0.27	0.21	77.1



Your result	0.11
Target value (ALTM)	0.17
Your BIS	
Standard Uncertainty	0.00
CCV	20

TB/TB 2 Antigen (IU/mL)

	n	Mean	SD	CV(%)
All methods [ALTM]	335	0.17	0.04	20.6
LIAISON QFTB (CLIA)	194	0.18	0.03	14.8
OTHER (Automated)	4	0.18	0.05	28.8
OTHER (Manual)	3	0.08	0.09	112.5
QuantiFERON TB (Auto ELISA)	80	0.16	0.04	23.9
QuantiFERON TB (Man ELISA)	48	0.17	0.05	30.3
SD Biosensor TB (Auto FIA)	3	0.24	0.10	39.1
VIDAS TB (EIA)	3	0.27	0.21	76.9



Your result	0.11
Target value (ALTM)	0.17
Your BIS	
Standard Uncertainty	0.00
CCV	20

Mitogen (IU/mL)

	n	Mean	SD	CV(%)
All methods [ALTM]	336	0.16	0.07	41.6
LIAISON QFTB (CLIA)	194	0.16	0.05	33.8
OTHER (Automated)	4	0.41	0.49	121.3
OTHER (Manual)	3	0.07	0.08	102.3
QuantiFERON TB (Auto ELISA)	81	0.16	0.04	26.4
QuantiFERON TB (Man ELISA)	48	0.17	0.06	35.8
SD Biosensor TB (Auto FIA)	3	0.37	0.19	51.1
VIDAS TB (EIA)	3	0.26	0.21	80.0



Your result	0.13
Target value (ALTM)	0.16
Your BIS	
Standard Uncertainty	0.00
CCV	20

UK NEQAS for Immunology, Immunochemistry and Allergy
Northern General Hospital, Sheffield, S5 7AU, UK. Tel: 0114 271 5715, Email: ukneqas@immqas.org.uk
Director: Mrs D Patel / Dr R Sargur, Centre Manager: Ms C Stanley

Published at 15:44 on Thursday 6 June 2024

Interferon Gamma - Specimen : 243-1







Performance Criteria

- Ideal ..... MRVIS < 50
- Good ..... MRVIS 50-100
- Adequate MRVIS 100-200
- Poor ..... MRVIS > 200 or SDBIS > 200

For further performance criteria information please see our website at www.immqas.org.uk.
If laboratories require further assistance please contact the centre.

UK NEQAS for Immunology, Immunochemistry and Allergy
Northern General Hospital, Sheffield, S5 7AU, UK. Tel: 0114 271 5715, Email: ukneqas@immqas.org.uk
Director: Mrs D Patel / Dr R Sargur, Centre Manager: Ms C Stanley

Published at 15:44 on Thursday 6 June 2024

Nil control

Your result :
Target response : <5

Method	n
Oxford Immunotec TSPOT.TB	49



Panel A

Your result :
Target response : <5

Method	n
Oxford Immunotec TSPOT.TB	49



Panel B

Your result :
Target response : <5

Method	n
Oxford Immunotec TSPOT.TB	49



Pos control

Your result :
Target response : <5

Method	n
Oxford Immunotec TSPOT. TB	49



UK NEQAS for Immunology, Immunochemistry and Allergy
Northern General Hospital, Sheffield, S5 7AU, UK. Tel: 0114 271 5715, Email: ukneqas@immqas.org.uk
Director: Mrs D Patel / Dr R Sargur, Centre Manager: Ms C Stanley

Published at 15:44 on Thursday 6 June 2024

Qualitative Results



Your result : Indeterminate
Designated response : Indeterminate
Your MIS : 0

Your OMIS : 0
(0=Good, 1=Adequate, >1=Poor)

Interferon Gamma
Elispot

Correct
Incorrect
See comments

Technical Interpretation



Your response : T3,T5,T12,T14
Designated response :
T3,T5,T7,T12,T14

Interferon Gamma
Elispot

Correct
Incorrect
See comments

Technical Interpretation code

T1 - Reactive to MTB
T2 - Non-Reactive to MTB
T3 - Indeterminate Response to MTB
T4 - QC satisfactory
T5 - QC unsatisfactory
T6 - Sample transposition
T7 - QC fail - PHA response poor
T8 - Wrong Specimen type
T9 - Sample mislabelling
T10 - QC fail - High negative background
T11 - Sample too old
T12 - Sample over/under filled
T13 - Repeat on same sample
T14 - Repeat with new sample
T15 - No Action

UK NEQAS for Immunology, Immunochemistry and Allergy
Northern General Hospital, Sheffield, S5 7AU, UK. Tel: 0114 271 5715, Email: ukneqas@immqas.org.uk
Director: Mrs D Patel / Dr R Sargur, Centre Manager: Ms C Stanley

Published at 15:44 on Thursday 6 June 2024

Clinical Interpretation



Clinical Interpretation code

O1 - Exposure: Consistent with exposure to TB
O2 - Exposure: No evidence of exposure to TB
O3 - Exposure: Internal QC failed
O4 - Exposure: Equivocal TB response
I1 - Illness: Consistent with exposure to TB
I2 - Illness: No evidence of exposure to TB
I3 - Illness: Internal QC failed
I4 - Illness: Equivocal TB response
P1 - Pre biologic: Consistent with exposure to TB
P2 - Pre biologic: No evidence of exposure to TB
P3 - Pre biologic: Internal QC failed
P4 - Pre biologic: Equivocal TB response
N1 - Insufficient details consistent with exposure to TB
N2 - Insufficient details no evidence of exposure to TB
N3 - Insufficient details internal QC failed
N4 - Insufficient details equivocal TB response
C1 - Clinical: Seek clinical advice
F1 - Probably TB with false negative tests - seek clinical assessment
X1 - Immunosuppressed: False negative can occur in Immunosuppressed

UK NEQAS for Immunology, Immunochemistry and Allergy
Northern General Hospital, Sheffield, S5 7AU, UK. Tel: 0114 271 5715, Email: ukneqas@immqas.org.uk
Director: Mrs D Patel / Dr R Sargur, Centre Manager: Ms C Stanley

Published at 15:44 on Thursday 6 June 2024

Interferon Gamma - Specimen : 243-2

389 / 448 (87%) laboratories returned results for this distribution.
Sample 243-2 was from a 54 year old female who was being tested as part of occupational health screening. She had a positive TST which required further investigation. This sample was linked to iEQA case 287.
Participants must register for the iEQA scheme to gain access to further clinical details. Please contact us if you require further information about iEQA registration.

The statistics for the VIDAS TB (EIA) method group are calculated against MLTM. However, as the minimum number of returned results required to make scoring statistically meaningful was not met for this method group, it will not be subject to variance index scoring.

Your MRVIS is 101
Your MRBIS is -48
Your SDBIS is 110

Nil (IU/mL)

	n	Mean	SD	CV(%)
All methods [ALTM]	337	0.17	0.05	26.4
LIAISON QFTB (CLIA)	194	0.17	0.02	13.2
OTHER (Automated)	3	0.13	0.03	18.9
OTHER (Manual)	3	0.12	0.03	26.1
QuantiFERON TB (Auto ELISA)	82	0.17	0.05	27.8
QuantiFERON TB (Man ELISA)	49	0.17	0.06	33.3
SD Biosensor TB (Auto FIA)	3	0.22	0.08	33.6
VIDAS TB (EIA)	3	0.38	0.03	6.6



Your result 0.46
Target value (ALTM) 0.17
Your BIS
Standard Uncertainty 0.00
CCV 20

TB 1 Antigen (IU/mL)

	n	Mean	SD	CV(%)
All methods [ALTM]	330	0.16	0.06	38.1
LIAISON QFTB (CLIA)	193	0.17	0.03	15.4
OTHER (Automated)	3	0.15	0.03	18.8
OTHER (Manual)	3	0.09	0.08	81.8
QuantiFERON TB (Auto ELISA)	79	0.15	0.06	41.5
QuantiFERON TB (Man ELISA)	49	0.18	0.06	32.1
VIDAS TB (EIA)	3	0.26	0.22	83.4



Your result 0.38
Target value (ALTM) 0.16
Your BIS
Standard Uncertainty 0.00
CCV 20

TB/TB 2 Antigen (IU/mL)

	n	Mean	SD	CV(%)
All methods [ALTM]	336	0.16	0.07	41.2
LIAISON QFTB (CLIA)	194	0.16	0.06	36.9
OTHER (Automated)	4	0.14	0.05	40.3
OTHER (Manual)	3	0.09	0.08	93.3
QuantiFERON TB (Auto ELISA)	81	0.15	0.06	41.6
QuantiFERON TB (Man ELISA)	48	0.17	0.05	27.9
SD Biosensor TB (Auto FIA)	3	0.32	0.04	12.8
VIDAS TB (EIA)	3	0.26	0.22	83.4



Your result 0.16
Target value (ALTM) 0.16
Your BIS
Standard Uncertainty 0.00
CCV 20

Mitogen (IU/mL)

	n	Mean	SD	CV(%)
All methods [ALTM]	337	2.24	0.37	16.5
LIAISON QFTB (CLIA)	194	2.33	0.28	11.8
OTHER (Automated)	4	1.65	0.43	25.8
OTHER (Manual)	2	2.02	0.70	34.6
QuantiFERON TB (Auto ELISA)	82	2.13	0.36	17.1
QuantiFERON TB (Man ELISA)	49	2.03	0.42	20.5
SD Biosensor TB (Auto FIA)	3	3.62	0.57	15.6
VIDAS TB (EIA)	3	4.69	0.55	11.8



Your result 1.82
Target value (ALTM) 2.24
Your BIS -93
Standard Uncertainty 0.03
CCV 20

UK NEQAS for Immunology, Immunochemistry and Allergy
Northern General Hospital, Sheffield, S5 7AU, UK. Tel: 0114 271 5715, Email: ukneqas@immqas.org.uk
Director: Mrs D Patel / Dr R Sargur, Centre Manager: Ms C Stanley

Published at 15:44 on Thursday 6 June 2024

Interferon Gamma - Specimen : 243-2







Performance Criteria

- Ideal ..... MRVIS < 50
- Good ..... MRVIS 50-100
- Adequate MRVIS 100-200
- Poor ..... MRVIS > 200 or SDBIS > 200

For further performance criteria information please see our website at www.immqas.org.uk.
If laboratories require further assistance please contact the centre.

UK NEQAS for Immunology, Immunochemistry and Allergy
Northern General Hospital, Sheffield, S5 7AU, UK. Tel: 0114 271 5715, Email: ukneqas@immqas.org.uk
Director: Mrs D Patel / Dr R Sargur, Centre Manager: Ms C Stanley

Published at 15:44 on Thursday 6 June 2024

Nil control

Your result :
Target response : <5

Method	n
Oxford Immunotec TSPOT.TB	50



Panel A

Your result :
Target response : <5

Method	n
Oxford Immunotec TSPOT.TB	50



Panel B

Your result :
Target response : <5

Method	n
Oxford Immunotec TSPOT.TB	50



Pos control

Your result :
Target response : >20

Method	n
Oxford Immunotec TSPOT. TB	50



UK NEQAS for Immunology, Immunochemistry and Allergy
Northern General Hospital, Sheffield, S5 7AU, UK. Tel: 0114 271 5715, Email: ukneqas@immqas.org.uk
Director: Mrs D Patel / Dr R Sargur, Centre Manager: Ms C Stanley

Published at 15:44 on Thursday 6 June 2024

Qualitative Results



Your result : Negative
Designated response : Negative
Your MIS : 0

Your OMIS : 0
(0=Good, 1=Adequate, >1=Poor)

Interferon Gamma
Elispot

Correct
Incorrect
See comments

Technical Interpretation



Your response : T2,T4,T15
Designated response : T2,T4,T15

Interferon Gamma
Elispot

Correct
Incorrect
See comments

Technical Interpretation code

T1 - Reactive to MTB
T2 - Non-Reactive to MTB
T3 - Indeterminate Response to MTB
T4 - QC satisfactory
T5 - QC unsatisfactory
T6 - Sample transposition
T7 - QC fail - PHA response poor
T8 - Wrong Specimen type
T9 - Sample mislabelling
T10 - QC fail - High negative background
T11 - Sample too old
T12 - Sample over/under filled
T13 - Repeat on same sample
T14 - Repeat with new sample
T15 - No Action

UK NEQAS for Immunology, Immunochemistry and Allergy
Northern General Hospital, Sheffield, S5 7AU, UK. Tel: 0114 271 5715, Email: ukneqas@immqas.org.uk
Director: Mrs D Patel / Dr R Sargur, Centre Manager: Ms C Stanley

Published at 15:44 on Thursday 6 June 2024

Clinical Interpretation



Clinical Interpretation code

O1 - Exposure: Consistent with exposure to TB
O2 - Exposure: No evidence of exposure to TB
O3 - Exposure: Internal QC failed
O4 - Exposure: Equivocal TB response
I1 - Illness: Consistent with exposure to TB
I2 - Illness: No evidence of exposure to TB
I3 - Illness: Internal QC failed
I4 - Illness: Equivocal TB response
P1 - Pre biologic: Consistent with exposure to TB
P2 - Pre biologic: No evidence of exposure to TB
P3 - Pre biologic: Internal QC failed
P4 - Pre biologic: Equivocal TB response
N1 - Insufficient details consistent with exposure to TB
N2 - Insufficient details no evidence of exposure to TB
N3 - Insufficient details internal QC failed
N4 - Insufficient details equivocal TB response
C1 - Clinical: Seek clinical advice
F1 - Probably TB with false negative tests - seek clinical assessment
X1 - Immunosuppressed: False negative can occur in Immunosuppressed

UK NEQAS for Immunology, Immunochemistry and Allergy
Northern General Hospital, Sheffield, S5 7AU, UK. Tel: 0114 271 5715, Email: ukneqas@immqas.org.uk
Director: Mrs D Patel / Dr R Sargur, Centre Manager: Ms C Stanley

Published at 15:44 on Thursday 6 June 2024

Comments :
The response rate was good for distribution 243 with 87% (389/448) of participants submitting a result.

Qualitative and Quantitative results :

Sample 243-1 :
An indeterminate qualitative response was reported by 375/389 of the laboratories that submitted a result for sample 243-1. Three laboratories reported a positive result, and eleven laboratories reported a negative result for this sample. Five laboratories appear to have transposed their results with sample 243-2. Laboratories that are out of consensus should check their results.

Sample 243-2 :
A negative qualitative response was reported by 378/389 of the laboratories that submitted a result for sample 243-2. Six laboratories reported a positive result, and five laboratories reported an indeterminate result for this sample. Five laboratories appear to have transposed their results with sample 243-1. Laboratories that are out of consensus should check their results.

Technical Interpretation :

Sample 243-1 :
There were 376 responses for sample 243-1 with 361 laboratories reporting comment (T3) Indeterminate Response to MTB, 201 of these laboratories reported (T5) QC unsatisfactory, 161 reported (T7) QC fail –PHA response poor, and of these; 146 laboratories reported comment (T14) Repeat with a new sample. 19 laboratories reported (T12) sample under/overfilled which was indicated within the iEQA case. There was also information in the case about issues with the time of sample collection.
Thirteen laboratories did not submit a technical response.

Sample 243-2 :
There were 377 responses for sample 243-2 with 368 laboratories reporting comment (T2) Non-Reactive to MTB, 345 of these laboratories also reported (T4) QC satisfactory, and of these; 175 laboratories reported comment (T15) No action.
Twelve laboratories did not submit a technical response.

Clinical Interpretation :

Sample 243-1 :
For sample 243-1, there were 280 responses of which 146 laboratories submitted comment (O3) Exposure: Internal QC failed. 106 of these laboratories reported comment (I3) Illness: Internal QC failed, and of these, 67 laboratories reported comment (C1) Clinical: Seek clinical advice.
Various other clinical comments were reported by laboratories and participants should review the iEQA case to assess if these are appropriate.

109/389 laboratories did not report a clinical interpretation for sample 243-1.

Sample 243-2 :
For sample 243-2, there were 285 responses of which 273 laboratories submitted (O2) Exposure: No evidence of exposure to TB, 91 of these laboratories also reported comment (C1) Clinical: Seek clinical advice.
Various other clinical comments were reported by laboratories and participants should review the iEQA case to assess if these are appropriate.

104/389 laboratories did not report a clinical interpretation for sample 243-2.

The answers to iEQA cases 286 and 287 are now available. Please refer to these cases for more details about interpretation

Reminder :
Please remember you must register for the iEQA scheme to gain access to further clinical details.
Participants registered for the UK NEQAS for Interferon Gamma Release Assays (Mycobacterium tuberculosis) are provided with free of charge access to iEQA for 1 user.

The next distribution (244) will be linked to the necessary clinical details on the UK NEQAS Immunology interpretative scheme (iEQA) **www.immqas.org.uk.**
We would encourage any laboratory that is not currently registered for UK NEQAS Immunology interpretative scheme (iEQA) to contact us for further information. There is much useful educational material in the cases for both scientists and clinicians that highlight the importance of the correct use and interpretation of the assay.

Published at 15:44 on Thursday 6 June 2024